Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230042/S005

Optune Lua

Novocure, GmbH · Decision date Jan 7, 2026

FDA DECISIONP230042/S005

What did the FDA decide?

FDA records P230042/S005 as a supplement to PMA P230042, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 7, 2026.

FDA approval order statement

addition of a second-source supplier (TDK) for the for the lead-free ceramic discs used with the Optune Lua ITE Transducer Arrays.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Anesthesiology
Decision date
Jan 7, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P230042/S005
Regulatory pathway
PMA supplement
Product code
SDA
Decision code
OK30
Decision date
Jan 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Electrical tumor treatment fields for non-small cell lung cancer.

Product code
SDA
FDA device class
3

For the original device and its historical approval scope, see PMA P230042. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230042/S005 received

    Application receipt date recorded by FDA.

  2. P230042/S005 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P230042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230042

Product / regulatory recordCompanyPathwayDecision dateSource
Optune LuaP230042
Novocure, GmbHPMA approvalOct 15, 2024FDA
Optune LuaP230042/S001
Novocure, GmbHPMA supplementAug 12, 2025FDA
Optune LuaP230042/S004
Novocure, GmbHPMA supplementOct 8, 2025FDA
Optune LuaP230042/S007
Novocure, GmbHPMA supplementFeb 25, 2026FDA
Optune LuaP230042/S008
Novocure, GmbHPMA supplementJul 1, 2026FDA
Optune LuaP230042/S010
Novocure, GmbHPMA supplementOct 26, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Novocure, GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Neuhofstrasse 21, Baar, 6340

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records